"New York Oncology Hematology (NYOH) is the leading provider of community-based cancer care and blood disorder services. With six convenient locations in Albany, Amsterdam, Clifton Park in Saratoga County, Hudson, and Troy, our team of 35 physicians and more than 350 cancer care specialists see more than 100,000 cancer visits a year."

During the past decade, New York Oncology Hematology, P.C. conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 55 clinical trials were completed, i.e. on average, 148.6% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 24 clinical trials were completed. i.e. 266.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Oncology Hematology, P.C." #1 sponsor was "US Oncology Research" with 12 trials, followed by "Hoffmann-La Roche" with 10 trials sponsored, "NSABP Foundation Inc" with 8 trials sponsored, "Celgene" with 7 trials sponsored and "Seagen Inc." with 7 trials sponsored. Other sponsors include 72 different institutions and companies that sponsored additional 55 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Oncology Hematology, P.C." #1 collaborator was "National Cancer Institute (NCI)" with 10 trials as a collaborator, "Bristol-Myers Squibb" with 6 trials as a collaborator, "Genentech, Inc." with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator and "Pfizer" with 3 trials as a collaborator. Other collaborators include 28 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "New York Oncology Hematology, P.C." are "Breast Cancer" (18 trials), "Non-Small Cell Lung Cancer" (6 trials), "Prostate Cancer" (6 trials), "Metastatic Breast Cancer" (5 trials) and "Small Cell Lung Cancer" (5 trials). Many other conditions were trialed in "New York Oncology Hematology, P.C." in a lesser frequency.

Most popular intervention types in "New York Oncology Hematology, P.C." are "Drug" (113 trials), "Biological" (8 trials), "Other" (8 trials), "Radiation" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (12 trials), "Docetaxel" (11 trials), "Atezolizumab" (8 trials), "Cyclophosphamide" (8 trials) and "Gemcitabine" (7 trials). Other intervention names were less common.

The vast majority of trials in "New York Oncology Hematology, P.C." are 94 trials for "All" genders, 15 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "New York Oncology Hematology, P.C.". undefined are not yet recruiting, 7 are recruiting, 24 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 74 completed trials in New York Oncology Hematology, P.C., undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in New York Oncology Hematology, P.C., 15 "Phase 1" clinical trials were conducted, 50 "Phase 2" clinical trials and 58 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".